Published in Medical Letter on the CDC and FDA, March 4th, 2007
The company reported a net income for the fourth quarter of $90,000 compared to a net loss of $407,000 fourth quarter of 2005.
Among highlights for the quarter was receiving approval from the United States Food and Drug Administration (FDA) for the "pocket protector" indication for the use of the D-Stat Flowable hemostat following pacemaker and ICD implants.
Vascular Solutions also received FDA clearances to launch the new 023 version of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA